Pieris is the project coordinator of the Consortium, responsible for scientific management. The company, in addition to providing PRS-080 candidate molecule, contributes key intellectual property for the Anticalin® technology, characterization and optimization of the PRS-080 molecule, assay development, CMC formulation and development experience.

Pieris Pharmaceuticals GmbH, (www.pieris.com) is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create safer, more efficacious and more convenient protein therapeutics. Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches. Pieris’ pipeline ranges from its Phase I compound, PRS-050 (anti-VEGF, oncology), to multiple Anticalins in preclinical development. The company has four ongoing discovery and development collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan. Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures.

For more information about the company or the project, please contact info "at" pieris-ag.com. For media inquiries, please contact media "at" pieris-ag.com.